Skip to content

Study · Animal study (in vivo) · rat · 2016

3 results

Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance.

Wiśniewski K, Sueiras-Diaz J, Jiang G, Galyean R, Lu M, Thompson D, Wang YC, Croston G, Posch A, Hargrove DM, Wiśniewska H, Laporte R and 10 more

Show all authors

Dwyer JJ, Qi S, Srinivasan K, Hartwig J, Ferdyan N, Mares M, Kraus J, Alagarsamy S, Rivière PJ, Schteingart CD

Journal of medicinal chemistry25 Mar 2016Cited by 30 (Europe PMC)

PMID26986178 (opens in a new tab)DOI10.1021/acs.jmedchem.5b01909 (opens in a new tab)PepBankPUB-26986178
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, FE 203799 clearance was below 0.3 mL/min/kg.

    In plain wordsIn rats, FE 203799 clearance was below 0.3 mL/min/kg.

    Peptide
    Apraglutide
    Outcome
    Not applicableSystemic clearance
    Study

    ratn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Clearance
    < 0.3 mL/min/kg
    rat

    Source sentences

    Summary
    displayed the desired profiles (EC50 (hGLP-2R) < 100 pM, CL in rat <0.3 mL/min/kg, selective vs hGLP-1R and hGCGR).
    2 context sentences
    Summary · context
    In vitro receptor potency at the human GLP-2, selectivity vs the human GLP-1 and GCG receptors, and PK profile in rats were determined for the new analogues.
    Summary · context
    Compound 73 (FE 203799) was selected as a candidate for clinical development.
  2. 02LabIn vitro (cells)Activity measurement

    In receptor assays, FE 203799 had a human GLP-2 receptor EC50 below 100 pM.

    In plain wordsIn lab tests, FE 203799 had a GLP-2 receptor EC50 below 100 pM.

    Peptide
    Apraglutide
    Outcome
    Not applicableGLP-2 receptor potency
    Study

    humann: not reported in source

    human GLP-2 receptor assay
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    EC50
    < 100 pM
    hGLP-2R

    Source sentences

    Summary
    displayed the desired profiles (EC50 (hGLP-2R) < 100 pM, CL in rat <0.3 mL/min/kg, selective vs hGLP-1R and hGCGR).
    2 context sentences
    Summary · context
    In vitro receptor potency at the human GLP-2, selectivity vs the human GLP-1 and GCG receptors, and PK profile in rats were determined for the new analogues.
    Summary · context
    Compound 73 (FE 203799) was selected as a candidate for clinical development.
  3. 03LabIn vitro (cells)Activity measurement

    In receptor assays, FE 203799 was selective for hGLP-2R versus hGLP-1R and hGCGR.

    In plain wordsIn lab tests, FE 203799 selectively targeted hGLP-2R compared with hGLP-1R and hGCGR.

    Peptide
    Apraglutide
    Outcome
    Not applicableReceptor selectivity
    Study

    humann: not reported in source

    human receptor assays
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    displayed the desired profiles (EC50 (hGLP-2R) < 100 pM, CL in rat <0.3 mL/min/kg, selective vs hGLP-1R and hGCGR).
    2 context sentences
    Summary · context
    In vitro receptor potency at the human GLP-2, selectivity vs the human GLP-1 and GCG receptors, and PK profile in rats were determined for the new analogues.
    Summary · context
    Compound 73 (FE 203799) was selected as a candidate for clinical development.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.